Advertising in the Euroasian Journal of Hepato-Gastroenterology: A Complete Guide for Pharma and Medical Brands in India

Most pharmaceutical marketing managers we speak with have never considered advertising in a peer-reviewed medical journal — and the ones who have are often surprised to discover that the Euroasian Journal of Hepato-Gastroenterology delivers something that no Instagram campaign or programmatic display network can replicate: a captive, credentialed, clinically-minded audience that is actively reading about the very disease areas your product treats. The journal, published by Jaypee Brothers Medical Publishers (P) Ltd. out of New Delhi, carries ISSN 2231-5047 for its print edition and ISSN 2231-5128 for its online edition — two numbers that matter more than most advertisers realise, because they signal a formally registered, internationally recognised publication with a verified editorial identity. At SmartAds, we have managed media placements across dozens of Indian medical journals, and EJOHG consistently sits in a category of its own when it comes to reaching gastroenterologists, hepatologists, and specialist clinicians across the Euroasian region.

Why Should Pharma Brands Advertise in the Euroasian Journal of Hepato-Gastroenterology?

The honest answer is that most brands get their medical journal advertising strategy backwards. They treat journal placements as a prestige exercise — a logo in a respected publication — rather than as a precision targeting tool. What a lot of people miss is that the Euroasian Journal of Hepato-Gastroenterology is not a general-interest medical title; it is a specialist gastroenterology journal read almost exclusively by gastroenterologists, hepatologists, and allied clinicians who are actively engaged in managing conditions like hepatitis B, hepatocellular carcinoma, inflammatory bowel disease, and other gastrointestinal diseases prevalent across India and the broader Euroasian region. When a pharmaceutical company places a full-page advertisement in EJOHG, it is not buying general awareness — it is buying direct access to prescribing physicians at the exact moment they are deepest in clinical thinking.

The journal is published under the auspices of the Euroasian Gastroenterological Association and maintains close ties with the Indian Society of Gastroenterology, which means its readership is not just geographically distributed but professionally organised. Clinicians and scientists who read EJOHG tend to be key opinion leaders (KOL) within their institutions — department heads, academic consultants, and senior practitioners whose prescribing decisions carry downstream influence over their juniors and residents. We have found, across campaigns we have managed for pharma companies in India, that a single well-placed ad in a journal like this one generates a quality of brand recall that is qualitatively different from digital impressions; the reader is not scrolling past your ad in three seconds between reels — they are sitting with the journal, often in a clinical setting, with their professional identity fully engaged.

On top of that, the gastrointestinal disease burden in India creates an urgent commercial context for advertisers. Liver disease, including hepatitis B and hepatocellular carcinoma, affects tens of millions of Indians; the gastroenterology therapeutics market is one of the fastest-growing segments within Indian pharma, and the pipeline of new drugs targeting the gut-liver axis means that competition for mindshare among specialist physicians is intensifying. Advertising in the Euroasian Journal of Hepato-Gastroenterology is, frankly speaking, one of the most cost-efficient ways for a pharma brand to maintain consistent visibility with this exact audience — particularly when combined with a broader medical journal advertising strategy across complementary titles.

What Advertising Formats Are Available in EJOHG Magazine?

Print advertising in EJOHG follows the conventional hierarchy that most pharma media planners will recognise, but the specifics matter enormously for budget planning. The most premium placement is the back cover advertisement, which commands the highest rate and delivers the highest passive visibility — it is the face of the journal when it sits on a desk or in a waiting room. The inside cover ad positions, both front and back, are the next tier; these are the first and last things a reader sees when they open or close the journal, which makes them disproportionately memorable relative to interior placements. Full-page advertisements within the editorial body of the journal are the workhorse format — they sit alongside peer-reviewed content, which means the reader's attention is already fully engaged when they encounter your brand message. Half-page and quarter-page formats are also available and represent a sensible entry point for brands that want to test the medium before committing to premium positions.

What a lot of advertisers do not explore fully is the digital advertising inventory that EJOHG makes available through its online platform on JaypeeDigital and through www.jaypeejournals.com. Banner advertisement placements on the journal's digital properties allow brands to reach the growing segment of clinicians who access the journal online — and this segment is growing faster than most print-focused media planners account for. The e-TOC alert advertising option is particularly interesting to us: when a new issue is published, subscribers receive an email table-of-contents alert, and advertising placement within that alert means your brand message lands in the inbox of every active subscriber at the moment of peak engagement with the journal. In our experience, e-TOC alert open rates for specialist medical journals in India tend to run considerably higher than general marketing email benchmarks, somewhere in the range of 35 to 50 percent, which makes this a genuinely high-value digital touchpoint.

Sponsored supplement advertising represents a third, and in many ways the most powerful, format available in EJOHG. A sponsored supplement is a dedicated issue or section of the journal — produced to the same editorial standards as the main publication — that is underwritten by a single advertiser, typically a pharmaceutical company, and distributed alongside or as part of a regular issue. These supplements can cover clinical case compilations, therapeutic review articles, or continuing medical education (CME) content, all of which carry the journal's peer-reviewed credibility while serving the advertiser's educational marketing objectives. Jaypee Brothers Medical Publishers has a well-established process for managing sponsored supplements, and the editorial independence of the content is carefully maintained — which is precisely what gives these supplements their value. At SmartAds, we always tell our clients that a sponsored supplement in a journal like EJOHG is not just advertising; it is a piece of branded scientific communication that can be reprinted, distributed at conferences, and circulated among key opinion leaders for months after publication.

Who Is the Target Audience of EJOHG and Why Does It Matter for Advertisers?

The readership of the Euroasian Journal of Hepato-Gastroenterology is defined by its editorial scope, which covers the full spectrum of hepatology and gastroenterology — from basic science to clinical practice — across the Euroasian region, with a particularly strong concentration in South Asia and India. The core audience consists of gastroenterologists and hepatologists in private practice, academic medical centres, and government hospitals; this is supplemented by a meaningful readership among general physicians with a subspecialty interest in digestive diseases, as well as researchers, fellows, and postgraduate students in relevant disciplines. Clinicians and scientists who publish in or subscribe to EJOHG tend to be among the more academically engaged practitioners in their field — the kind of healthcare professionals who attend national conferences, participate in clinical trials, and influence prescribing patterns within their peer networks.

From a pharmaceutical advertising standpoint, this audience profile is exceptionally valuable. Prescribing physicians in gastroenterology and hepatology are the primary decision-makers for a wide range of high-value drug categories — proton pump inhibitors, antiviral agents for hepatitis B, biologics for inflammatory bowel disease, antifibrinotics, and the emerging class of non-alcoholic steatohepatitis (NASH) therapies, among others. The targeted medical audience that EJOHG delivers is not just large in absolute terms; it is concentrated in exactly the specialties where pharmaceutical advertising India needs to be most precise. We have seen campaigns where a pharma brand achieved better recall scores among gastroenterologists through a single issue placement in a journal like EJOHG than through three months of digital banner advertising across general medical portals — and the reason is straightforward: context is everything in professional media.

What is also worth noting, and what most media plans overlook, is that the EJOHG audience extends beyond India into the broader Euroasian region — Central Asia, the Middle East, and parts of Eastern Europe — which makes it relevant for pharmaceutical companies with regional ambitions, not just domestic ones. For a brand launching a product in multiple South Asian markets simultaneously, the Euroasian Gastroenterological Association's journal provides a single placement that crosses multiple geographies. To be fair, the dominant readership concentration is in India, and most advertisers rightly treat it as an India-first vehicle; but the international dimension adds a layer of credibility and reach that purely domestic journals cannot match.

How Is EJOHG Indexed and What Does That Mean for Your Ad's Credibility?

Indexing is, frankly speaking, the single most important quality signal in the medical journal world — and it is the dimension that most advertising decision-makers either do not understand or do not think to ask about. The Euroasian Journal of Hepato-Gastroenterology is indexed in PubMed and PubMed Central (PMC), which are the gold-standard databases maintained by the National Center for Biotechnology Information (NCBI) under the US National Library of Medicine. Being a PubMed indexed journal means that every article published in EJOHG is discoverable by clinicians and researchers worldwide through the most widely used medical literature search platform in existence; it means the journal has passed a rigorous editorial quality review conducted by the National Library of Medicine; and it means that your advertisement appears in a publication that the global medical community recognises as scientifically credible.

Beyond PubMed and PMC indexed status, EJOHG is also listed in Index Copernicus and is preserved through PORTICO, the digital preservation service that ensures the journal's content — and by extension, your advertising placements — remains accessible and archived for the long term. The journal operates under a Creative Commons CC-BY-NC 4.0 license for its open-access content, which means articles are freely available online and the journal's reach extends well beyond its paid subscriber base. The ISSN 2231-5047 for print and ISSN 2231-5128 for online are registered with the ISSN International Centre, and the journal's open-access status is verified through Sherpa Romeo — all of which are signals that matter to the increasingly sophisticated pharma marketing teams who are now doing due diligence on publication quality before committing advertising budgets.

Here is where it gets interesting from a media planning perspective: the indexing status of a journal is not just a credibility signal for the editorial content — it directly affects the value of your advertisement. A pharma brand whose ad appears in a PubMed indexed journal is, by association, positioned alongside content that meets international scientific standards; this is a form of contextual brand equity that simply cannot be replicated in a non-indexed trade publication or a digital health portal. At SmartAds, we have worked with pharmaceutical companies that were initially sceptical about the premium associated with indexed journal advertising, and in every case, once we walked them through the audience quality and contextual credibility argument, the conversation shifted from "is this worth it?" to "how do we get the best placement?"

What Are the Steps to Book an Advertisement in EJOHG in India?

The booking process for advertising in the Euroasian Journal of Hepato-Gastroenterology runs through Jaypee Brothers Medical Publishers (P) Ltd., which is headquartered in New Delhi, Daryaganj — one of the historic centres of Indian medical publishing. The first step is to contact the journal's advertising department, either directly or through a media buying agency, to request the current media kit, which contains the rate card, technical specifications for ad artwork, and the editorial calendar showing issue dates and submission deadlines. Given that EJOHG is a half-yearly publication — a bi-annual journal that releases two issues per year — the advertising calendar is relatively concentrated, which means planning ahead is not optional; it is essential.

Once the format and placement have been agreed upon, the advertiser submits artwork according to the technical specifications provided by Jaypee Brothers Medical Publishers. For print advertising, this typically means high-resolution PDF or TIFF files at 300 DPI, with bleed and trim marks as specified; for digital banner advertisement placements, the specifications include standard IAB dimensions, though the exact pixel requirements should be confirmed with the publisher at the time of booking. The editorial approval process for pharmaceutical advertisements is a step that first-time advertisers sometimes underestimate — all drug promotion materials placed in Indian medical journals must comply with applicable regulations, and the publisher's team will review submitted creatives for compliance before confirming placement. We have seen this step cause delays of one to two weeks when advertisers submit materials that require revision, so building compliance review time into your production schedule is something we strongly recommend.

Payment terms and cancellation policies vary and should be clarified in writing at the time of booking. In our experience managing medical journal advertising India placements, most publishers require full payment before the print deadline, and cancellation after artwork submission may result in partial or full forfeiture of the booking fee — particularly for premium positions like the back cover advertisement or inside cover ad, which are difficult to resell on short notice. Working through an experienced media buying partner like SmartAds means these terms are negotiated and documented upfront, and the production timeline is managed to avoid last-minute complications that can be costly.

How Much Does It Cost to Advertise in a Jaypee Brothers Medical Journal?

We are asked this question in almost every client conversation, and the honest answer is that Jaypee Brothers Medical Publishers does not publish a publicly available rate card for EJOHG — which is actually quite common among specialist Indian medical journals, where rates are negotiated based on placement, frequency, and the nature of the advertiser relationship. What we can share, based on our experience with comparable Jaypee Brothers Medical Publishers titles and the broader Indian medical journal advertising market, is a realistic sense of the cost landscape. A full-page advertisement in a well-indexed specialist journal of this calibre typically works out to somewhere between ₹50,000 and ₹1,20,000 per insertion, depending on placement — with back cover and inside cover positions commanding a premium of roughly 40 to 60 percent over standard interior full-page rates.

To put that in context: the CPM for a targeted medical audience of this quality works out to a number that surprises most first-time advertisers when they compare it to what they are paying for programmatic digital reach across general health portals. Digital display advertising might deliver a lower absolute cost per impression, but the quality of that impression — a specialist clinician reading a peer-reviewed gastroenterology journal versus a general internet user who happens to have visited a health website — is incomparable. Sponsored supplement advertising packages, which include production, editorial coordination, and distribution, are priced considerably higher, typically in the ballpark of ₹3 lakh to ₹8 lakh or more depending on the scope and length of the supplement; these are investment-level placements that make most sense for brands with a significant product launch or a major clinical data communication objective.

Reprint advertising and e-print packages add another dimension to the cost-benefit calculation. A reprint is a physical reproduction of a published article — often a clinical study or review that mentions your product — which can be ordered in bulk from Jaypee Brothers Medical Publishers and distributed by your medical representatives at conferences, in doctor's offices, or through direct mail. An e-print is the digital equivalent, a high-quality PDF of the article that can be shared electronically. Bulk subscription packages, which sometimes include the option to have your company logo on the cover or a co-branded insert, are available for organisations that want to ensure their key accounts receive the journal consistently. Advertising rates for all of these formats are best obtained through a direct inquiry or through a media buying partner who has an existing relationship with the publisher.

What Are the Regulatory Guidelines for Pharmaceutical Advertising in Indian Medical Journals?

This is the section that most media planning guides skip over, and it is precisely the section that gets pharma marketing teams into trouble. Pharmaceutical advertising in India is governed by a layered regulatory framework, and every advertisement placed in a journal like the Euroasian Journal of Hepato-Gastroenterology must be compliant with all applicable rules before it goes to press. The foundational legislation is the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954, which prohibits the advertisement of certain categories of drugs and imposes strict standards on claims made in drug promotion materials. Alongside this sits the CDSCO regulations administered by the Central Drugs Standard Control Organisation, which govern the approval and marketing of pharmaceutical products in India.

The self-regulatory layer that is most directly relevant to medical journal advertising is the Uniform Code of Pharmaceutical Marketing Practices (UCPMP), which was introduced by the Department of Pharmaceuticals and has been progressively strengthened. UCPMP code compliance requires that all promotional materials for prescription drugs be accurate, balanced, and supported by current evidence; claims must be consistent with the approved prescribing information; and comparative claims must be substantiated. Frankly speaking, most of the violations we see in pharma journal advertising are not deliberate — they arise from marketing teams using global brand materials that have not been adapted for the Indian regulatory context, or from overstating efficacy claims in ways that are permissible in some markets but not in India. The Indian Medical Council (IMC) Regulations 2002 also impose obligations on healthcare professionals regarding the receipt of gifts and benefits from pharmaceutical companies, which has implications for how sponsored content and CME-linked advertising is structured.

At SmartAds, we work with our pharmaceutical advertising clients to review creative materials against the UCPMP framework before submission to any publisher, including Jaypee Brothers Medical Publishers. This is not a legal service — we always recommend that clients have their regulatory affairs team sign off on final materials — but our media planning team has enough familiarity with the common compliance pitfalls to flag issues early and avoid the delays and costs that come with rejected submissions. The editorial team at EJOHG, like most reputable peer-reviewed journals, conducts its own review of advertising content for obvious compliance issues; but the primary responsibility for regulatory compliance rests with the advertiser, and that responsibility cannot be outsourced to the publisher.

How Does EJOHG Compare to Other Gastroenterology Journals for Advertising in India?

The Indian medical journal landscape for gastroenterology and hepatology advertising is more varied than most media planners realise, and choosing the right vehicle — or the right combination of vehicles — requires a clear-eyed comparison of reach, credibility, audience quality, and cost. The most direct comparator to the Euroasian Journal of Hepato-Gastroenterology is the Indian Journal of Gastroenterology, which is the official publication of the Indian Society of Gastroenterology and has a longer publishing history within the domestic market. The Indian Journal of Gastroenterology has a strong ISG membership readership base, which gives it deep penetration among practising gastroenterologists in India; EJOHG, by contrast, has a broader geographic mandate through the Euroasian Gastroenterological Association and a strong open-access profile through its PMC indexed status, which arguably gives it greater international discoverability.

What a lot of brands miss when comparing these two journals is that the audience overlap is significant but not complete — there are gastroenterologist readers of EJOHG who do not subscribe to the Indian Journal of Gastroenterology, and vice versa. A media plan that includes both journals therefore delivers broader coverage of the specialist gastroenterologist audience than either title alone, and the combined cost is still a fraction of what a comparable reach campaign would cost through digital channels targeting healthcare professionals. We worked with a pharmaceutical company launching a hepatitis B treatment a couple of years ago — a mid-sized Indian pharma brand, not one of the large multinationals — and the combination of EJOHG and one other Jaypee Brothers title delivered measurably better recall among hepatologists in our post-campaign survey than the digital-only approach the brand had used for its previous product launch.

To be fair, there are contexts in which other journals may be more appropriate. If a brand's primary objective is reaching general physicians rather than specialists, a broader-circulation title like the Journal of the Association of Physicians of India (JAPI) may be more efficient. If the target is academic researchers rather than clinicians, a higher-impact international journal may be worth the premium. But for a pharmaceutical or medical device company whose primary commercial objective is influencing prescribing behaviour among gastroenterologists and hepatologists in India and the Euroasian region, the Euroasian Journal of Hepato-Gastroenterology sits at a very compelling intersection of audience quality, indexing credibility, and advertising accessibility — and it is a vehicle that, in our view, remains underutilised relative to its actual value.

What Is the ROI of Advertising in Peer-Reviewed Medical Journals in India?

Journal advertising ROI is one of the harder metrics to quantify in pharmaceutical marketing, and we will be honest about that rather than offer false precision. Unlike digital advertising, where click-through rates and conversion tracking can be measured in real time, print advertising in a medical journal operates through a longer, more diffuse influence pathway — brand exposure leads to recall, recall influences prescribing consideration, and prescribing consideration eventually shows up in sales data, but the attribution chain is long and subject to many confounding variables. What the industry does have, however, is a substantial body of research on physician media consumption and the relative influence of different information sources on prescribing decisions; and that research, much of which is referenced in reports from bodies like the Indian Council of Medical Research and the Indian Medical Association, consistently shows that peer-reviewed journals rank among the most trusted sources of clinical information for specialist physicians.

The practical implication for advertisers is that medical journal advertising works through a trust transfer mechanism: the credibility of the journal transfers to the brands that advertise within it, particularly when the advertising is contextually relevant to the editorial content. A hepatology drug advertised in a hepatology journal is not just reaching the right audience — it is reaching that audience in a mental context of clinical engagement and scientific receptivity that is simply not available in any other media format. One pharmaceutical client we worked with — a company marketing a proton pump inhibitor to gastroenterologists in South India — reported that their medical representatives were receiving more informed, substantive conversations with doctors in the months following a print advertising campaign in EJOHG and a companion journal, which the brand attributed to increased journal-driven awareness of their clinical data.

The FICCI-EY Media and Entertainment Report and the Dentsu e4m India Digital Report both track the broader shift of pharma advertising budgets toward digital channels; and while that shift is real and the growth of online advertising in healthcare is undeniable, the reports also note that specialist print media — particularly peer-reviewed journals — has maintained its influence among high-value professional audiences in ways that general consumer print has not. The GroupM TYNY Report has similarly noted that healthcare remains one of the sectors where print advertising retains a disproportionate share of spend relative to its overall market decline, precisely because of the professional audience dynamic. Our view at SmartAds is that the most effective pharmaceutical advertising India strategies are not digital-versus-print choices — they are integrated plans that use journal advertising for credibility and specialist reach, and digital channels for frequency and broader coverage.

Reprint, E-Print and Bulk Subscription Advertising Packages in EJOHG

Reprint advertising is one of the most underappreciated tools in the pharmaceutical marketing arsenal, and it is worth spending some time on it because the way it is used in practice is quite different from how it is described in most media guides. When a clinical study or review article published in the Euroasian Journal of Hepato-Gastroenterology contains data that is commercially relevant to a pharma brand — a favourable efficacy comparison, a safety profile analysis, a disease burden study — the brand can commission a reprint of that article from Jaypee Brothers Medical Publishers, which produces a high-quality physical reproduction of the published piece. These reprints are then distributed by medical representatives as leave-behind materials, which carry the full credibility of the peer-reviewed journal masthead and the PubMed indexed journal citation.

The e-print is the digital equivalent — a PDF version of the published article, formatted to match the journal's design and carrying the journal's branding — which can be distributed electronically, embedded in email communications to healthcare professionals, or made available for download through a brand's medical affairs portal. The distinction between a reprint and an e-print matters for regulatory purposes: both are governed by the same UCPMP code compliance requirements as any other promotional material, and the use of reprints for drug promotion is specifically addressed in Indian pharmaceutical marketing guidelines. The key rule is that reprints must represent the complete, unmodified published article — selective excerpting or highlighting of specific data points in a way that creates a misleading impression is not permissible.

Bulk subscription packages represent a third category of value-add advertising in EJOHG, one that is particularly relevant for pharmaceutical companies, medical device manufacturers, and diagnostic companies that want to ensure consistent journal access for a defined group of healthcare professionals. Under a bulk subscription arrangement, a company purchases a specified number of subscriptions — typically for their key accounts, their medical advisory board members, or the attendees of a sponsored CME event — and the journal is delivered to those individuals for the subscription period. Some bulk subscription packages include the option to have the sponsoring company's logo on the cover or a co-branded insert within the journal, which provides ongoing brand visibility at a relatively modest incremental cost. Advertising packages that combine a print insertion with a bulk subscription and a reprint order represent some of the best value in the EJOHG advertising inventory, in our experience.

Frequently Asked Questions About Advertising in the Euroasian Journal of Hepato-Gastroenterology

Q: How can I place an advertisement in the Euroasian Journal of Hepato-Gastroenterology?

Advertisements in EJOHG are booked through Jaypee Brothers Medical Publishers (P) Ltd. in New Delhi, either by contacting the publisher's advertising department directly or through a media buying agency with an existing relationship with the Jaypee Brothers network. The process involves requesting the current media kit and rate card, confirming your preferred format and placement, submitting artwork to the publisher's technical specifications, and completing payment before the issue's print deadline. Working through a media buying partner like SmartAds.in streamlines this process considerably, as the agency handles the rate negotiation, artwork coordination, compliance pre-review, and deadline management on behalf of the advertiser — which is particularly valuable for brands that are new to medical journal advertising India or that are managing multiple simultaneous placements across several journals.

Q: What are the available advertising formats in EJOHG magazine (print and online)?

The print advertising formats available in EJOHG include the back cover advertisement, inside cover ad positions (both front and back inside covers), full-page advertisements within the editorial body, and half-page formats. On the digital side, banner advertisement placements are available on the journal's online platforms including JaypeeDigital and www.jaypeejournals.com, and e-TOC alert advertising allows brands to place their message within the email notification sent to all subscribers when a new issue is published. Sponsored supplement advertising, which involves the production and distribution of a dedicated branded supplement issue, is available as a premium format. Reprint and e-print packages, as well as bulk subscription arrangements with co-branding options, round out the full advertising packages available through the publisher.

Q: What is the readership and audience profile of EJOHG for pharmaceutical advertisers?

The Euroasian Journal of Hepato-Gastroenterology is read primarily by gastroenterologists, hepatologists, and specialist clinicians across India and the Euroasian region, with a strong concentration in South Asia. The audience includes both practising clinicians and academic researchers, with a significant proportion of key opinion leaders (KOL) in the gastroenterology and hepatology fields. The journal's association with the Euroasian Gastroenterological Association and its PubMed indexed status means that its readership skews toward the more academically engaged and clinically active segment of the specialist physician community — precisely the prescribing physicians and healthcare professionals who have the greatest influence over drug selection in their institutions and peer networks.

Q: Is EJOHG indexed in PubMed and what does that mean for my advertisement's credibility?

Yes, the Euroasian Journal of Hepato-Gastroenterology is a PubMed indexed journal and is also indexed in PubMed Central (PMC), which represents the highest tier of indexing available for biomedical journals. For advertisers, this matters because PubMed indexing is the primary quality signal that the physician community uses to evaluate the credibility of a journal; a brand whose advertisement appears in a PubMed indexed journal benefits from the contextual credibility that indexing confers. The journal is also listed in Index Copernicus and is preserved through PORTICO, and its open-access content operates under a Creative Commons CC-BY-NC 4.0 license — all of which contribute to its international discoverability and the quality of the audience it attracts.

Q: What are the advertising submission deadlines for EJOHG print issues?

Since EJOHG is a half-yearly publication — a bi-annual journal that publishes two issues per year — the advertising calendar has two primary booking windows. Specific submission deadlines vary by issue and should be confirmed with Jaypee Brothers Medical Publishers at the time of inquiry, as they depend on the print production schedule for each issue. As a general rule, artwork and payment for print advertising should be submitted at least four to six weeks before the intended issue date to allow for editorial review, compliance checking, and production. We strongly recommend that advertisers planning to place in EJOHG make their booking inquiry at least two to three months before the target issue, particularly for premium positions like the back cover advertisement or inside cover ad, which are typically reserved early.

Q: How much does it cost to advertise in the Euroasian Journal of Hepato-Gastroenterology?

Jaypee Brothers Medical Publishers does not maintain a publicly available rate card for EJOHG, and advertising rates are provided upon inquiry. Based on our experience with comparable Jaypee Brothers Medical Publishers titles and the broader Indian specialist journal market, full-page interior placements typically work out to somewhere in the range of ₹50,000 to ₹1,20,000 per insertion, with premium positions like the back cover and inside covers commanding a meaningful premium over those figures. Sponsored supplement packages are priced significantly higher, reflecting the production and editorial coordination involved. Reprint and e-print orders are priced per unit based on quantity, and bulk subscription packages are priced per subscription. Contact SmartAds.in for a customised rate inquiry and media plan.

Q: What regulatory guidelines apply to pharmaceutical advertisements in Indian medical journals like EJOHG?

Pharmaceutical advertising in Indian medical journals is governed by the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954, the CDSCO regulations under the Drugs and Cosmetics Act, the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) issued by the Department of Pharmaceuticals, and the Indian Medical Council (IMC) Regulations 2002. All promotional materials must be accurate, balanced, and consistent with approved prescribing information; claims must be substantiated by current clinical evidence; and comparative claims require robust evidentiary support. UCPMP code compliance is the primary self-regulatory framework that pharma companies are expected to follow, and its provisions specifically address the content and format of journal advertisements, sponsored supplements, and reprint distribution. Advertisers are advised to have their regulatory affairs team review all materials before submission.

Q: Can I sponsor a supplement issue in the Euroasian Journal of Hepato-Gastroenterology?

Yes, sponsored supplement advertising is available in EJOHG through Jaypee Brothers Medical Publishers, and it represents one of the most impactful formats available to pharmaceutical advertisers. A sponsored supplement is a dedicated section or separate issue of the journal — produced to the same editorial and production standards as the main publication — that is underwritten by a single sponsor and typically covers a specific clinical topic, case series, or therapeutic area review. The editorial content of the supplement is subject to the same peer-review and editorial independence standards as the main journal, which is what gives sponsored supplements their credibility. The approval timeline for sponsored supplements is longer than for standard display advertising — typically three to six months from concept to publication — and the content must comply fully with UCPMP and CDSCO regulations. Brands planning a major product launch or a significant clinical data communication campaign should consider a sponsored supplement as part of their integrated pharma journal advertising strategy.

Q: What is the difference between e-print and reprint advertising options in EJOHG?

A reprint is a physical, printed reproduction of a published article from EJOHG, produced by Jaypee Brothers Medical Publishers to the same design and quality standards as the original journal. Reprints are ordered in bulk and are typically used by pharmaceutical medical representatives as leave-behind materials during physician visits. An e-print is the digital equivalent — a high-quality PDF of the published article — which can be distributed electronically, shared via email, or made available for download. Both formats carry the journal's masthead and citation details, which is the source of their credibility as promotional tools. From a regulatory standpoint, both reprints and e-prints used for drug promotion must comply with UCPMP code compliance requirements and must represent the complete, unmodified published article. The choice between the two depends on the distribution channel: field force distribution favours physical reprints, while digital medical affairs communications favour e-prints.

Q: How does advertising in EJOHG compare to digital pharma marketing for gastroenterology products in India?

The two channels are not really in competition — they serve different functions in the media mix, and the most effective campaigns we have managed use both. Digital pharma marketing, whether through programmatic display, medical portal advertising, or social media targeting of healthcare professionals, offers scale, frequency, and real-time measurement; it is excellent for maintaining brand awareness across a broad base of physicians and for driving traffic to medical affairs resources. Journal advertising in EJOHG, by contrast, offers depth of engagement, contextual credibility, and access to a highly specific targeted medical audience in a professional reading context that digital channels cannot replicate. The Dentsu e4m India Digital Report and the FICCI-EY Media Report both note the continued growth of digital advertising in healthcare, but the data also shows that specialist print media retains its influence among high-prescribing specialists — and gastroenterology is precisely the kind of specialty where that dynamic is most pronounced.

Q: What is the publication frequency of EJOHG and how does it affect my advertising schedule?

The Euroasian Journal of Hepato-Gastroenterology is a half-yearly publication, meaning it releases two issues per year — making it a bi-annual journal. This publication frequency has direct implications for advertising planning: with only two issues annually